Ligand-based receptor tyrosine kinase partial agonists: New paradigm for cancer drug discovery?
DJ Riese - Expert opinion on drug discovery, 2011 - Taylor & Francis
Introduction: Receptor tyrosine kinases (RTKs) are validated targets for oncology drug
discovery and RTK antagonists are available to treat human malignancies. Nonetheless, the …
discovery and RTK antagonists are available to treat human malignancies. Nonetheless, the …
Ligand-based receptor tyrosine kinase partial agonists: New paradigm for cancer drug discovery?
DJ Riese 2nd - Expert opinion on drug discovery, 2011 - pubmed.ncbi.nlm.nih.gov
INTRODUCTION: Receptor tyrosine kinases (RTKs) are validated targets for oncology drug
discovery and several RTK antagonists have been approved for the treatment of human …
discovery and several RTK antagonists have been approved for the treatment of human …
[HTML][HTML] Ligand-based receptor tyrosine kinase partial agonists: New paradigm for cancer drug discovery?
DJ Riese - Expert opinion on drug discovery, 2011 - ncbi.nlm.nih.gov
Abstract Introduction—Receptor tyrosine kinases (RTKs) are validated targets for oncology
drug discovery and several RTK antagonists have been approved for the treatment of …
drug discovery and several RTK antagonists have been approved for the treatment of …
[PDF][PDF] Ligand-based receptor tyrosine kinase partial agonists: New paradigm for cancer drug discovery?
DJ Riese II - Expert Opin Drug Discov. Author manuscript; available …, 2012 - academia.edu
Abstract Introduction—Receptor tyrosine kinases (RTKs) are validated targets for oncology
drug discovery and several RTK antagonists have been approved for the treatment of …
drug discovery and several RTK antagonists have been approved for the treatment of …
[引用][C] Ligand-based receptor tyrosine kinase partial agonists: new paradigm for cancer drug discovery?
DJ Riese - Expert Opinion on Drug Discovery, 2011 - cir.nii.ac.jp
Ligand-based receptor tyrosine kinase partial agonists: new paradigm for cancer drug
discovery? | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …
discovery? | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …
Ligand-based receptor tyrosine kinase partial agonists: New paradigm for cancer drug discovery?
DJ Riese 2nd - Expert Opinion on Drug Discovery, 2011 - europepmc.org
Abstract Introduction—Receptor tyrosine kinases (RTKs) are validated targets for oncology
drug discovery and several RTK antagonists have been approved for the treatment of …
drug discovery and several RTK antagonists have been approved for the treatment of …